[14C]-4-aminobutyric acid | 21195-45-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [14C]-4-aminobutyric acid
• 英文别名: 4-Amino-(4-14C)-buttersaeure；γ-Amino-buttersaeure(4-¹⁴C)；4-Aminobuttersaeure；4-amino-[4-¹⁴C]butyric acid；4-amino(414C)butanoic acid
• CAS: 21195-45-9
• 化学式: C₄H₉NO₂
• 分子量: 105.11
• InChiKey: BTCSSZJGUNDROE-YZRHJBSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [14C]-4-aminobutyric acid 、 2-(叔丁氧羰基氧亚氨基)-2-苯乙腈 在 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 以219.4 mg的产率得到[14C]-4-N-tert-butoxycarbonylaminobutyric acid
  参考文献：
  名称：

  A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished Extrapyramidal Effects

  摘要：

  The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.

  DOI：

  10.1021/jm7012453
• 作为产物：
  描述：

  [14C-cyano]-3-cyanopropanoic acid 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 以 异丙醇 为溶剂， 反应 2.0h， 生成 [14C]-4-aminobutyric acid
  参考文献：
  名称：

  A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished Extrapyramidal Effects

  摘要：

  The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.

  DOI：

  10.1021/jm7012453

文献信息

• A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished Extrapyramidal Effects
  作者：Abraham Nudelman、Irit Gil-Ad、Nava Shpaisman、Igor Terasenko、Hanna Ron、Kinneret Savitsky、Yona Geffen、Abraham Weizman、Ada Rephaeli

  DOI：10.1021/jm7012453

  日期：2008.5.1

  The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.